Pro-Dex (PDEX) to Release Earnings on Wednesday

Pro-Dex (NASDAQ:PDEX) is projected to post its Q3 2026 results before the market opens on Wednesday, April 29th. Analysts expect the company to announce earnings of $0.62 per share and revenue of $17.90 million for the quarter. Parties may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Friday, May 1, 2026 at 4:00 PM ET.

Pro-Dex (NASDAQ:PDEX) last issued its earnings results on Thursday, January 29th. The medical instruments supplier reported $0.66 EPS for the quarter, topping the consensus estimate of $0.59 by $0.07. Pro-Dex had a return on equity of 22.53% and a net margin of 15.73%.The company had revenue of $18.66 million during the quarter, compared to the consensus estimate of $17.30 million.

Pro-Dex Stock Performance

Shares of NASDAQ PDEX opened at $52.10 on Monday. The company has a current ratio of 4.03, a quick ratio of 2.25 and a debt-to-equity ratio of 0.19. Pro-Dex has a 12 month low of $23.47 and a 12 month high of $70.25. The stock has a 50 day moving average of $47.75 and a 200-day moving average of $40.53. The company has a market capitalization of $167.24 million, a P/E ratio of 15.32 and a beta of -0.11.

Institutional Investors Weigh In On Pro-Dex

Several institutional investors and hedge funds have recently made changes to their positions in PDEX. Los Angeles Capital Management LLC bought a new position in Pro-Dex in the fourth quarter worth approximately $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Pro-Dex in the second quarter worth approximately $50,000. Bank of America Corp DE increased its position in shares of Pro-Dex by 173.3% during the second quarter. Bank of America Corp DE now owns 1,692 shares of the medical instruments supplier’s stock valued at $74,000 after acquiring an additional 1,073 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Pro-Dex by 65.4% during the fourth quarter. Wells Fargo & Company MN now owns 2,314 shares of the medical instruments supplier’s stock worth $89,000 after buying an additional 915 shares during the last quarter. Finally, New York State Common Retirement Fund bought a new stake in Pro-Dex in the second quarter worth about $105,000. Institutional investors own 15.28% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Pro-Dex in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

About Pro-Dex

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.